一氧化氮在阿片耐受中的作用

一氧化氮在阿片耐受中的作用阿片耐受的机理至今还不清楚,一系列复杂的因素在阿片耐受过程中发挥着作用,兴奋性氨基酸ＮＭＤＡ受体可能参与吗啡耐受的形成,因为ＮＭＤＡ受体拮抗剂可延缓吗啡耐受的发生。近年来的工作表明,激活ＮＭＤＡ受体引起的作用有一部分是通过Ｎ...     

竞争性NMDA受体拮抗剂

ＭＮＤＡ受体拮抗剂主要分为二大类,即竞争性拮抗剂和非竞争性拮抗剂,本文综述了竞争性ＮＭＤＡ受体拮抗剂的研究进展。     

NMDA和非NMDA受体拮抗剂对伤害性辐射热引起的缩腿反射抑制的比较

我们以前的电生理工作：Ｎ－甲基－Ｄ－门冬氨酸受体主要参与介导皮肤来源的伤害性信息的传入,而非ＮＭＤＡ受体主要参与介导肌肉来源的伤害性信息的传入。为进一步证实这一发现,应用鞘内注射的方法,观察ＮＭＤＡ和非ＮＭＤＡ受体拮抗剂对大鼠伤害性辐射热刺激所引起的缩腿反射潜伏期的影响。     

兴奋性氨基酸在缺氧耐受形成中的变化

在缺血缺氧性脑损伤中 ,兴奋性氨基酸 (ＥＡＡ)起重要作用。但ＥＡＡ在缺氧耐受形成中的作用尚未见报道。本实验通过观察ＥＡＡ的ＮＭＤＡ(Ｎ 甲基 Ｄ 天门冬氨酸 )受体激动剂Ｌ ＧＬＵ(Ｌ 谷氨酸 )、受体拮抗剂氯氨酮对缺氧耐受的影响及在缺氧耐受中ＥＡＡ和抑制性氨基酸的变化 ,旨在初步探讨缺氧耐受的机制。1　材料与方法(1)试剂　Ｌ ＧＬＵ(上海伯奥生物科技公司 ) ;氯氨酮 (美国Ｓｉｇｍａ公司 ) ;ＡＱＣ(6 氨基喹啉 Ｎ 羟基 琥珀酰亚胺基甲酸酯 )及 18种氨基酸标准品 (美国Ｗａｔｅｒｓ公司 ) ;Ｄ 正亮氨酸 (中国科学院生物技术厂…     

氯氨酮和L-NAME抑制模拟高原低氧大鼠下丘脑NOS和生长抑素mRNA的表达

用高原低氧模型及原位杂交、ＮＡＤＰＨ－ｄ组织化学法,探讨氯氨酮和Ｌ－ＮＡＭＥ对急性高原低氧大鼠下丘脑一氧化氮合酶（ＮＯＳ）和生长抑素ｍＲＮＡ（ＳＳ ｍＲＮＡ）表达的影响。结果表明,急性高原低氧引起下丘脑ＮＯＳ和ＳＳ ｍＲＮＡ过度表达,如先用ＮＭＤＡ受体拮抗剂氯氨酮和ＮＯＳ抑制剂Ｌ－ＮＡＭＥ预处理,ＮＯＳ和ＳＳ ｍＲＮＡ的表达均明显被抑制。结果提示,ＮＭＤＡ受体参与了急生高原低氧引起的下丘脑ＮＯＳ和     

实验性癫痫时海马内一氧化氮合酶的变化及其与谷氨酸受体的关系

应用免疫组织化学方法观察了青霉素致痫时海马内神经元型一氧化氮合酶（ｎＮＯＳ）表达的时程变化及海马内微量注射ＮＭＤＡ受体拮抗剂ＭＫ－８０１（５－ｍｅｔｈｙｌ－１０,１１－ｄｉｈｙｄｒｏ－５Ｈ－ｄｉｂｅｎｚｏ［ａ,ｄ］ｃｙｃｌｏｈｅｐｔａｎ－５,１０－ｉｍｉｎｅｍａｌｅａｔｅ）和非ＮＭＤＡ受体拮抗剂ＤＮＱＸ（６,７－ｄｉｎｉｔｒｏｑｕｉｎｏｘａｌｉｎｅ－２,３－ｄｉｏｎｅ）对大鼠海马内ｎＮＯＳ表达的影     

NMDA受体与中枢神经系统发育

中枢神经系统兴奋性氨基酸离子型受体－ＮＭＤＡ受体,是由ＮＭＤＡＲ１和ＮＭＤＡＲ２两个亚单位共同构成的受体通道复合体。ＮＭＤＡ受本激活后可引起神经元细胞对Ｎａ＾＋,Ｋ＾＋和Ｃａ＾２＋通透性增强,产生兴奋性突触后电位,在中枢神经发育的过程中,ＮＭＤＡ受体通过不同亚型的选择性表达,改变自身的结构和功能,进而影响ＮＭＤＡ受体介导的Ｃａ＾２＋内流,调节神经元内Ｃａ＾２＋依赖的第二信使系统,最终实现对中枢神经     

内源性阿片物质参与大鼠缺血预处理的心肌保护作用

实验以离体灌流的ＳＤ大鼠心脏为模型,用ｋ特异性拮抗剂的ＭＲ２２６６研究ｋ阿片受体的阻断与缺血预处理的关系,用放射免疫分析法研究ＩＰ及长时间缺血对心肌强啡肽Ａ１－１３浓度的影响,探索Ｋ阿片物质在ＩＰ过程中的作用和地位。     

兴奋性氨基酸介导脊髓伤害性信息传递

ＮＭＤＡ和非ＮＭＤＡ受体广泛存在于猫脊髓背角神经元上,并参与介导伤害性信息传递;ＮＭＤＡ受体主要介导皮肤的伤害性传入,非ＮＭＤＡ受体则主要介导肌肉和内脏的伤害性传入;皮肤和肌肉的伤害性传入分别诱发释放更多的门冬氨酸和谷氨酸可能是这种差别的主要原因之一;ＮＭＤＡ受体的不同调节位点在伤害性信息传递中有密切的协同作用;兴奋性氨基酸和Ｐ物质及其受体在介导和调制伤害性信息传递中的相互作用可以分别发生在神经元     

小鼠大脑皮质N—甲基—D—天冬氨酸受体的鉴定及其的衰老时的变化

以放射性配基结合分析法对正常成年小鼠大脑皮中Ｎ－甲基－Ｄ－天冬氨酸（ＮＭＤＡ）受体作了鉴定;观察了衰老小鼠ＮＭＤＡ受体、空间辨别能力、海马突触传递长时程增强的变化及补肾中药复方对这些变化的影响。结果表明：小鼠大脑皮质含有丰富的、高亲和力的ＮＭＤＡ受体;衰老过程中小鼠ＮＭＤＡ受体的最大结合容量Ｂｍａｘ）呈渐进性降低,空间辨别能力下降,ＬＴＰ的振幅和斜率明显降低;补肾中药复方具有提高衰才小鼠ＮＭＤＡ受     

NMDA receptor antagonism disrupts the development of morphine analgesic tolerance in male, but not female C57BL/6J mice

Multiple studies demonstrate that coadministration of N-methyl-D-aspartate (NMDA) receptor antagonists with the opioid agonist morphine attenuates the development of analgesic tolerance. Sex differences in the effects of noncompetitive, but not competitive NMDA receptor antagonists on acute morphine analgesia, have been reported in mice, yet the role of sex in modulation of morphine tolerance by NMDA receptor antagonists has yet to be addressed. Therefore, we tested whether there is a sex difference in the effect of NMDA receptor antagonists on the development of morphine analgesic tolerance in C57BL/6J mice. Acutely, at a dose required to affect morphine tolerance in male mice, the noncompetitive NMDA receptor antagonist dizocilpine (MK-801) prolonged morphine analgesia similarly in both sexes in the hot plate and tail withdrawal assays. In the hot plate assay, coadministration of MK-801 or the competitive antagonist 3-(2-carboxpiperazin-4-yl)propyl-1-phosphanoic acid (CPP) with morphine attenuated the development of tolerance in male mice, while having no effect in females. Like normal and sham females, ovariectomized mice were similarly insensitive to the attenuation of morphine tolerance by MK-801 in the hot plate assay. Surprisingly, in the tail withdrawal assay, MK-801 facilitated the development of morphine-induced hyperalgesia and tolerance in males but not females. The results demonstrate that male mice are more sensitive to modulation of nociception and morphine analgesia after repeated coadministration of NMDA receptor antagonists. Furthermore, the underlying mechanisms are likely to be different from those mediating the sex difference in the modulation of acute morphine analgesia that has previously been reported.     

The effects of NMDA receptor antagonists on acute morphine antinociception in mice

Summary.  Antagonists of the N-methyl-d-aspartate (NMDA) receptor complex inhibit the development of tolerance to antinociceptive effects of morphine and upon acute administration, influence morphine antinociceptive activity. The analysis of numerous studies investigating acute interaction between NMDA receptor antagonists and morphine in mice indicate a variety of procedural differences and reveal that these compounds may potentiate, attenuate and produce no effect on morphine antinociception. The conditions responsible for such conflicting experimental outcome of acute interaction remain unclear. It appears that the effects of NMDA receptor antagonists on morphine tolerance are not causally related to their acute effects on morphine antinociception. Received July 6, 2001 Accepted August 6, 2001 Published online August 9, 2002     

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands

Opioid analgesic tolerance remains a considerable drawback to chronic pain management. The finding that concomitant administration of delta opioid receptor (DOR) antagonists attenuates the development of tolerance to mu opioid receptor (MOR) agonists has led to interest in producing bifunctional MOR agonist/DOR antagonist ligands. Herein, we present 7-benzylideneoxymorphone (6, UMB 246) displaying MOR partial agonist/DOR antagonist activity, representing a new lead for designing bifunctional MOR/DOR ligands.     

Effect of caerulein on decreased latency of passive avoidance response in rats treated with NMDA receptor antagonists

The effect of subcutaneous injection of caerulein on memory impairment induced by intracerebroventricular administration of NMDA receptor antagonists was examined in the passive avoidance response of the rat. When rats were treated with AP5, AP7, CPP or MK-801, the retention latencies decreased markedly. However, in rats that received caerulein immediately after the training trials, the latency increased to some extent. Pretreatment with caerulein and subsequent injection of the competitive NMDA receptor antagonists AP5, AP7 and CPP caused a more apparent increase in the latency. The noncompetitive NMDA receptor antagonist MK-801 was not affected by pretreatment with caerulein. The difference might be, at least in part, due to the sites of action of these NMDA receptor antagonists.     

Endogenous opioids and feeding behavior: A decade of further progress (2004–2014). A Festschrift to Dr. Abba Kastin

Functional elucidation of the endogenous opioid system temporally paralleled the creation and growth of the journal, Peptides, under the leadership of its founding editor, Dr. Abba Kastin. He was prescient in publishing annual and uninterrupted reviews on Endogenous Opiates and Behavior that served as a microcosm for the journal under his stewardship. This author published a 2004 review, “Endogenous opioids and feeding behavior: a thirty-year historical perspective”, summarizing research in this field between 1974 and 2003. The present review “closes the circle” by reviewing the last 10 years (2004–2014) of research examining the role of endogenous opioids and feeding behavior. The review summarizes effects upon ingestive behavior following administration of opioid receptor agonists, in opioid receptor knockout animals, following administration of general opioid receptor antagonists, following administration of selective mu, delta, kappa and ORL-1 receptor antagonists, and evaluating opioid peptide and opioid receptor changes in different food intake models.     

Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?

Opiates are the primary treatment for pain management in cancer patients reporting moderate to severe pain, and are being increasingly used for non-cancer chronic pain. However, prolonged administration of opiates is associated with significant problems including the development of antinociceptive tolerance, wherein higher doses of the drug are required over time to elicit the same amount of analgesia. High doses of opiates result in serious side effects such as constipation, nausea, vomiting, dizziness, somnolence, and impairment of mental alertness. In addition, sustained exposure to morphine has been shown to result in paradoxical pain in regions unaffected by the initial pain complaint, and which may also result in dose escalation, i.e. 'analgesic tolerance'. A concept that has been gaining considerable experimental validation is that prolonged use of opioids elicits paradoxical, abnormal pain. This enhanced pain state requires additional opioids to maintain a constant level of antinociception, and consequently may be interpreted as antinociceptive tolerance. Many substances have been shown to block or reverse antinociceptive tolerance. A non-inclusive list of examples of substances reported to block or reverse opioid antinociceptive tolerance include: substance P receptor (NK-1) antagonists, calcitonin gene-related peptide (CGRP) receptor antagonists, nitric oxide (NO) synthase inhibitors, calcium channel blockers, cyclooxygenase (COX) inhibitors, protein kinase C inhibitors, competitive and non-competitive antagonists of the NMDA (N-methyl-D-aspartate) receptor, AMPA (alpha-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid) antagonists, anti-dynorphin antiserum, and cholecystokinin (CCK) receptor antagonists. Without exception, these substances are also antagonists of pain-enhancing agents. Prolonged opiate administration indeed induces upregulation of substance P (SP) and calcitonin gene-related peptide (CGRP) within sensory fibers in vivo, and this is accompanied by an enhanced release of excitatory neurotransmitters and neuropeptides from primary afferent fibers upon stimulation. The enhanced evoked release of neuropeptides is correlated with the onset of abnormal pain states and opioid antinociceptive tolerance. Importantly, the descending pain modulatory pathway from the brainstem rostral ventromedial medulla (RVM) via the dorsolateral funiculus (DLF) is critical for maintaining the changes observed in the spinal cord, abnormal pain states and antinociceptive tolerance, because animals with lesion of the DLF did not show enhanced evoked neuropeptide release, or develop abnormal pain or antinociceptive tolerance upon sustained exposure to opiates. Microinjection of either lidocaine or a CCK antagonist into the RVM blocked both thermal and touch hypersensitivity as well as antinociceptive tolerance. Thus, prolonged opioid exposure enhances a descending pain facilitatory pathway from the RVM that is mediated at least in part by CCK activity and is essential for the maintenance of antinociceptive tolerance.     

Molecular and cellular mechanisms of the age-dependency of opioid analgesia and tolerance

ABSTRACT: The age-dependency of opioid analgesia and tolerance has been noticed in both clinical observation and laboratory studies. Evidence shows that many molecular and cellular events that play essential roles in opioid analgesia and tolerance are actually age-dependent. For example, the expression and functions of endogenous opioid peptides, multiple types of opioid receptors, G protein subunits that couple to opioid receptors, and regulators of G protein signaling (RGS proteins) change with development and age. Other signaling systems that are critical to opioid tolerance development, such as N-methyl-D-aspartic acid (NMDA) receptors, also undergo age-related changes. It is plausible that the age-dependent expression and functions of molecules within and related to the opioid signaling pathways, as well as age-dependent cellular activity such as agonist-induced opioid receptor internalization and desensitization, eventually lead to significant age-dependent changes in opioid analgesia and tolerance development.     

Modulation of NMDA Receptor Subunit mRNA in Butorphanol-Tolerant and —Withdrawing Rats

The NMDA receptor has been implicated in opioid tolerance and withdrawal. The effects of continuous infusion of butorphanol on the modulation of NMDA receptor subunit NR1, NR2A, NR2B, and NR2C gene expression were investigated by using in situ hybridization technique. Continuous intracerebroventricular (i.c.v.) infusion with butorphanol (26 nmol/l/h) resulted in significant modulations in the NR1, NR2A, and NR2B mRNA levels. The level of NR1 mRNA was significantly decreased in the cerebral cortex, thalamus, and CA1 area of hippocampus in butorphanol tolerant and withdrawal (7 h after stopping the infusion) rats. The NR2A mRNA was significantly decreased in the CA1 and CA3 of hippocampus in tolerant rats and increased in the cerebral cortex and dentate gyrus in butorphanol withdrawal rats. NR2B subunit mRNA was decreased in the cerebral cortex, caudate putamen, thalamus, CA3 of hippocampus in butorphanol withdrawal rats. No changes of NR1, NR2A, NR2C subunit mRNA in the cerebellar granule cell layer were observed in either butorphanol tolerant or withdrawal rats. Using quantitative ligand autoradiography, the binding of NMDA receptor ligand [³H]MK-801 was increased significantly in all brain regions except in the thalamus and hippocampus, at the 7 hr after stopping the butorphanol infusion. These results suggest that region-specific changes of NMDA receptor subunit mRNA (NR 1 and NR2) as well as NMDA receptor binding ([³H]MK-801) are involved in the development of tolerance to and withdrawal from butorphanol.     

Molecular pharmacology of human NMDA receptors

N-methyl-d-aspartate (NMDA) receptors are ionotropic glutamate receptors that mediate excitatory neurotransmission. NMDA receptors are also important drug targets that are implicated in a number of pathophysiological conditions. To facilitate the transition from lead compounds in pre-clinical animal models to drug candidates for human use, it is important to establish whether NMDA receptor ligands have similar properties at rodent and human NMDA receptors. Here, we compare amino acid sequences for human and rat NMDA receptor subunits and discuss inter-species variation in the context of our current knowledge of the relationship between NMDA receptor structure and function. We summarize studies on the biophysical properties of human NMDA receptors and compare these properties to those of rat orthologs. Finally, we provide a comprehensive pharmacological characterization that allows side-by-side comparison of agonists, un-competitive antagonists, GluN2B-selective non-competitive antagonists, and GluN2C/D-selective modulators at recombinant human and rat NMDA receptors. The evaluation of biophysical properties and pharmacological probes acting at different sites on the receptor suggest that the binding sites and conformational changes leading to channel gating in response to agonist binding are highly conserved between human and rat NMDA receptors. In summary, the results of this study suggest that no major detectable differences exist in the pharmacological and functional properties of human and rat NMDA receptors.     

孤啡肽受体的配体研究进展

孤啡肽(nociceptin或orphanin FQ)发现于1995年底, 它是阿片受体样受体(ORL1或LC 132) 的内源性配体,在痛觉调节、心血管系统、离子通道、依赖和耐受、学习和记忆等方面具有广泛的生物学活性. 最近几年, 对孤啡肽受体与相关配体构效关系的研究成为一个新的热点.对在研究构效关系过程中所发现的孤啡肽受体相关配体（片段、拮抗剂、激动剂、部分激动剂和阻断剂）的研究情况进行了介绍.